Compile Data Set for Download or QSAR
Report error Found 155 Enz. Inhib. hit(s) with all data for entry = 11861
TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653968(US11912682, Compound 66)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653971(US11912682, Compound 69)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653965(US11912682, Compound 63)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653967(US11912682, Compound 65)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM654030(US11912682, Compound 129)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653977(US11912682, Compound 75)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653976(US11912682, Compound 74)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653972(US11912682, Compound 70)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM654036(US11912682, Compound 135)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653975(US11912682, Compound 73)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM654016(US11912682, Compound 115)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM654013(US11912682, Compound 112)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653948(US11912682, Compound 46)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM654012(US11912682, Compound 111)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM654015(US11912682, Compound 114)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM654014(US11912682, Compound 113)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653961(US11912682, Compound 59)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM654025(US11912682, Compound 124)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM654027(US11912682, Compound 126)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653962(US11912682, Compound 60)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653956(US11912682, Compound 54)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM654023(US11912682, Compound 122)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653937(US11912682, Compound 35)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653938(US11912682, Compound 36)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653996(US11912682, Compound 94)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653932(US11912682, Compound 30)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM654009(US11912682, Compound 107)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM654011(US11912682, Compound 110)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM654010(US11912682, Compound 108)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653942(US11912682, Compound 40)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM654049(US11912682, Compound 149)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653984(US11912682, Compound 82)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM654051(US11912682, Compound 151)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653986(US11912682, Compound 84)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653980(US11912682, Compound 78)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653983(US11912682, Compound 81)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653982(US11912682, Compound 80)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653918(US11912682, Compound 16)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM654057(US11912682, Compound 157)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM654056(US11912682, Compound 156)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653925(US11912682, Compound 23)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM654052(US11912682, Compound 152)
Affinity DataIC50: 500nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653969(US11912682, Compound 67)
Affinity DataIC50: 800nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653970(US11912682, Compound 68)
Affinity DataIC50: 800nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653964(US11912682, Compound 62)
Affinity DataIC50: 800nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653966(US11912682, Compound 64)
Affinity DataIC50: 800nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653979(US11912682, Compound 77)
Affinity DataIC50: 800nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653978(US11912682, Compound 76)
Affinity DataIC50: 800nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653974(US11912682, Compound 72)
Affinity DataIC50: 800nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandPNGBDBM653953(US11912682, Compound 51)
Affinity DataIC50: 800nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2024
Entry Details
US Patent

Displayed 1 to 50 (of 155 total ) | Next | Last >>
Jump to: